Evaluation of Fetuses in the Preventive IVIG Therapy for Congenital Heart Block (PITCH) study

• DOI: 10.17615/1c9c-tw21
• Publication Date: 2010-01-01
• Authors: Deborah Friedman; Carolina Llanos; Peter Izmirly; Brigit Brock; John Byron; Joshua A. Copel; Karen Cummiskey; Mary Anne Dooley; Jill Foley; Cornelia Graves; C HENDERSHOTT; Richard Kates; Elena V. Komissarova; Michelle Miller; Emmanuelle Paré; Colin K. L. Phoon; Tracy Prosen; Dale Reisner; Eric Ruderman; Philip Samuels; Jerry K. Yu; Mimi Kim; Jill P. Buyon
• Keywords: Fetal heart

The recurrence rate of anti-SSA/Ro associated congenital heart block (CHB) is 17%. Reversal of 3rd degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, IVIG was evaluated as a preventative therapy for CHB.